P2Y(12) inhibitor monotherapy in patients undergoing percutaneous coronary intervention

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorCAPODANNO, Davide
dc.contributor.authorBABER, Usman
dc.contributor.authorBHATT, Deepak L.
dc.contributor.authorCOLLET, Jean-Philippe
dc.contributor.authorDANGAS, George
dc.contributor.authorFRANCHI, Francesco
dc.contributor.authorGIBSON, C. Michael
dc.contributor.authorGWON, Hyeon-Cheol
dc.contributor.authorKASTRATI, Adnan
dc.contributor.authorKIMURA, Takeshi
dc.contributor.authorLEMOS, Pedro A.
dc.contributor.authorLOPES, Renato D.
dc.contributor.authorMEHRAN, Roxana
dc.contributor.authorO'DONOGHUE, Michelle L.
dc.contributor.authorV, Sunil Rao
dc.contributor.authorROLLINI, Fabiana
dc.contributor.authorSERRUYS, Patrick W.
dc.contributor.authorSTEG, Philippe G.
dc.contributor.authorSTOREY, Robert F.
dc.contributor.authorVALGIMIGLI, Marco
dc.contributor.authorVRANCKX, Pascal
dc.contributor.authorWATANABE, Hirotoshi
dc.contributor.authorWINDECKER, Stephan
dc.contributor.authorANGIOLILLO, Dominick J.
dc.date.accessioned2023-02-23T15:07:33Z
dc.date.available2023-02-23T15:07:33Z
dc.date.issued2022
dc.description.abstractThe evolution of stent design has reduced the incidence of stent thrombosis, meaning that the duration of dual antiplatelet therapy after percutaneous coronary intervention (PCI) might be shortened. In this Review, the authors describe the current evidence base and ongoing clinical trials into the use of P2Y(12) inhibitor monotherapy after PCI. For 20 years, dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and a platelet P2Y(12) receptor inhibitor, has been the gold standard of antithrombotic pharmacology after percutaneous coronary intervention (PCI). In the past 5 years, several investigations have challenged this paradigm by testing the efficacy and safety of P2Y(12) inhibitor monotherapy (that is, without aspirin) following a short course of DAPT. Collectively, these studies suggested a reduction in the risk of major bleeding and no significant increase in thrombotic or ischaemic events compared with guideline-recommended DAPT. Current recommendations are evolving to inform clinical practice on the ideal candidates for P2Y(12) inhibitor monotherapy after PCI. Generalizing the results of studies of P2Y(12) inhibitor monotherapy requires a thorough understanding of their design, populations, interventions, comparators and results. In this Review, we provide an up-to-date overview on the use of P2Y(12) inhibitor monotherapy after PCI, including supporting pharmacodynamic and clinical evidence, practical recommendations and future directions.eng
dc.description.indexMEDLINE
dc.description.indexPubMed
dc.description.indexWoS
dc.description.indexScopus
dc.identifier.citationNATURE REVIEWS CARDIOLOGY, v.19, n.12, p.829-844, 2022
dc.identifier.doi10.1038/s41569-022-00725-6
dc.identifier.eissn1759-5010
dc.identifier.issn1759-5002
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/51789
dc.language.isoeng
dc.publisherNATURE PORTFOLIOeng
dc.relation.ispartofNature Reviews Cardiology
dc.rightsrestrictedAccesseng
dc.rights.holderCopyright NATURE PORTFOLIOeng
dc.subject.otherdual antiplatelet therapyeng
dc.subject.otherdrug-eluting stentseng
dc.subject.otherticagrelor plus aspirineng
dc.subject.otherpost-hoc analysiseng
dc.subject.otherantithrombotic therapyeng
dc.subject.otheratrial-fibrillationeng
dc.subject.otherclinical-outcomeseng
dc.subject.otherprasugrel monotherapyeng
dc.subject.othercardiovascular eventseng
dc.subject.othersecondary preventioneng
dc.subject.wosCardiac & Cardiovascular Systemseng
dc.titleP2Y(12) inhibitor monotherapy in patients undergoing percutaneous coronary interventioneng
dc.typearticleeng
dc.type.categoryrevieweng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.affiliation.countryEstados Unidos
hcfmusp.affiliation.countryFrança
hcfmusp.affiliation.countryCoréia do Sul
hcfmusp.affiliation.countryAlemanha
hcfmusp.affiliation.countryJapão
hcfmusp.affiliation.countryIrlanda
hcfmusp.affiliation.countryInglaterra
hcfmusp.affiliation.countrySuíça
hcfmusp.affiliation.countryBélgica
hcfmusp.affiliation.countryItália
hcfmusp.affiliation.countryisobe
hcfmusp.affiliation.countryisojp
hcfmusp.affiliation.countryisoch
hcfmusp.affiliation.countryisous
hcfmusp.affiliation.countryisoit
hcfmusp.affiliation.countryisofr
hcfmusp.affiliation.countryisokr
hcfmusp.affiliation.countryisode
hcfmusp.affiliation.countryisoie
hcfmusp.affiliation.countryisogb
hcfmusp.author.externalCAPODANNO, Davide:Univ Catania, Cardiothorac Vasc & Transplant Dept, Azienda Osped Univ Policlin Gaspare Rodol San Mar, Catania, Italy
hcfmusp.author.externalBABER, Usman:Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA
hcfmusp.author.externalBHATT, Deepak L.:Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA USA
hcfmusp.author.externalCOLLET, Jean-Philippe:Sorbonne Univ, Hop Pitie Salpetriere, AP HP, ACT Grp,INSERM UMRS1166,Inst Cardiol, Paris, France
hcfmusp.author.externalDANGAS, George:Icahn Sch Med Mt Sinai, Cardiovasc Inst, New York, NY 10029 USA
hcfmusp.author.externalFRANCHI, Francesco:Univ Florida, Coll Med, Jacksonville, FL 32209 USA
hcfmusp.author.externalGIBSON, C. Michael:Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA USA
hcfmusp.author.externalGWON, Hyeon-Cheol:Sungkyunkwan Univ, Samsung Med Ctr, Dept Cardiol, Sch Med, Seoul, South Korea
hcfmusp.author.externalKASTRATI, Adnan:Deutsch Herzzentrum Munich, Cardiol, Munich, Germany; Tech Univ Munich, Munich, Germany
hcfmusp.author.externalKIMURA, Takeshi:Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Kyoto, Japan
hcfmusp.author.externalLOPES, Renato D.:Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA
hcfmusp.author.externalMEHRAN, Roxana:Icahn Sch Med Mt Sinai, Cardiovasc Inst, New York, NY 10029 USA
hcfmusp.author.externalO'DONOGHUE, Michelle L.:Brigham & Womens Hosp, TIMI Study Grp, Boston, MA USA
hcfmusp.author.externalV, Sunil Rao:Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA
hcfmusp.author.externalROLLINI, Fabiana:Univ Florida, Coll Med, Jacksonville, FL 32209 USA
hcfmusp.author.externalSERRUYS, Patrick W.:Natl Univ Ireland Galway, Lambe Inst Translat Med & Curam, Galway, Ireland
hcfmusp.author.externalSTEG, Philippe G.:Univ Paris, Hop Bichat, AP HP, INSERM U1148, Paris, France
hcfmusp.author.externalSTOREY, Robert F.:Univ Sheffield, Dept Infect Immun & Cardiovasc Dis, Sheffield, S Yorkshire, England
hcfmusp.author.externalVALGIMIGLI, Marco:Ente Osped Cantonal, Cardioctr Ticino Inst, Lugano, Switzerland; Bern Univ Hosp, Bern, Switzerland
hcfmusp.author.externalVRANCKX, Pascal:Univ Hasselt, Fac Med & Life Sci, Jessaziekenhuis, Dept Cardiol & Crit Care Med, Hasselt, Belgium
hcfmusp.author.externalWATANABE, Hirotoshi:Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Kyoto, Japan
hcfmusp.author.externalWINDECKER, Stephan:Bern Univ Hosp, Dept Cardiol, Inselspital, Bern, Switzerland
hcfmusp.author.externalANGIOLILLO, Dominick J.:Univ Florida, Coll Med, Jacksonville, FL 32209 USA
hcfmusp.citation.scopus33
hcfmusp.contributor.author-fmusphcPEDRO ALVES LEMOS NETO
hcfmusp.description.beginpage829
hcfmusp.description.endpage844
hcfmusp.description.issue12
hcfmusp.description.volume19
hcfmusp.origemWOS
hcfmusp.origem.pubmed35697777
hcfmusp.origem.scopus2-s2.0-85131864232
hcfmusp.origem.wosWOS:000810316200003
hcfmusp.publisher.cityBERLINeng
hcfmusp.publisher.countryGERMANYeng
hcfmusp.relation.referenceAngiolill DJ, 2020, J AM COLL CARDIOL, V75, P2403, DOI 10.1016/j.jacc.2020.03.008eng
hcfmusp.relation.referenceAngiolillo DJ, 2007, J AM COLL CARDIOL, V49, P1505, DOI 10.1016/j.jacc.2006.11.044eng
hcfmusp.relation.referenceAngiolillo DJ, 2022, EUROINTERVENTION, V17, pE1371, DOI 10.4244/EIJ-D-21-00904eng
hcfmusp.relation.referenceAngiolillo DJ, 2021, JACC-CARDIOVASC INTE, V14, P1434, DOI 10.1016/j.jcin.2021.04.043eng
hcfmusp.relation.referenceAngiolillo DJ, 2021, CIRCULATION, V143, P583, DOI 10.1161/CIRCULATIONAHA.120.050438eng
hcfmusp.relation.referenceAngiolillo DJ, 2020, JACC-CARDIOVASC INTE, V13, P606, DOI 10.1016/j.jcin.2020.01.226eng
hcfmusp.relation.referenceArmstrong PCJ, 2011, J THROMB HAEMOST, V9, P552, DOI 10.1111/j.1538-7836.2010.04160.xeng
hcfmusp.relation.referenceBaber U, 2020, EUR HEART J, V41, P3533, DOI 10.1093/eurheartj/ehaa670eng
hcfmusp.relation.referenceBaber U, 2020, J AM COLL CARDIOL, V75, P578, DOI 10.1016/j.jacc.2019.11.056eng
hcfmusp.relation.referenceBhatt DL, 2019, LANCET, V394, P1169, DOI 10.1016/S0140-6736(19)31887-2eng
hcfmusp.relation.referenceBhatt DL, 2002, AM J CARDIOL, V90, P625, DOI 10.1016/S0002-9149(02)02567-5eng
hcfmusp.relation.referenceUS National Library of Medicine, 2020, USeng
hcfmusp.relation.referenceUS National Library of Medicine, 2022, USeng
hcfmusp.relation.referenceUS National Library of Medicine, 2021, USeng
hcfmusp.relation.referenceValgimigli M, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1332eng
hcfmusp.relation.referenceVogel B, 2021, JAMA CARDIOL, V6, P1032, DOI 10.1001/jamacardio.2021.1720eng
hcfmusp.relation.referenceVranckx P, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.119.015560eng
hcfmusp.relation.referenceVranckx P, 2019, LANCET, V394, P1335, DOI 10.1016/S0140-6736(19)31872-0eng
hcfmusp.relation.referenceVranckx P, 2018, LANCET, V392, P940, DOI 10.1016/S0140-6736(18)31858-0eng
hcfmusp.relation.referenceWang RT, 2021, EUR HEART J-CARD PHA, V7, P547, DOI 10.1093/ehjcvp/pvab035eng
hcfmusp.relation.referenceWatanabe H, 2022, JAMA CARDIOL, V7, P407, DOI 10.1001/jamacardio.2021.5244eng
hcfmusp.relation.referenceWatanabe H, 2021, CARDIOVASC INTERV TH, V36, P403, DOI 10.1007/s12928-020-00719-6eng
hcfmusp.relation.referenceWatanabe H, 2021, CARDIOVASC INTERV TH, V36, P91, DOI 10.1007/s12928-020-00651-9eng
hcfmusp.relation.referenceWatanabe H, 2019, CIRCULATION, V140, P1957, DOI 10.1161/CIRCULATIONAHA.119.043613eng
hcfmusp.relation.referenceWatanabe H, 2019, JAMA-J AM MED ASSOC, V321, P2414, DOI 10.1001/jama.2019.8145eng
hcfmusp.relation.referenceYamamoto K, 2021, CIRC-CARDIOVASC INTE, V14, P469, DOI 10.1161/CIRCINTERVENTIONS.120.010384eng
hcfmusp.relation.referenceYun KH, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.620906eng
hcfmusp.relation.referenceYun KH, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.120.018366eng
hcfmusp.relation.referenceZhao Q, 2018, JAMA-J AM MED ASSOC, V319, P1677, DOI 10.1001/jama.2018.3197eng
hcfmusp.relation.referenceBhatt DL, 2001, CIRCULATION, V103, P363eng
hcfmusp.relation.referenceBhatt DL, 2000, AM HEART J, V140, P67, DOI 10.1067/mhj.2000.108239eng
hcfmusp.relation.referenceBonaca MP, 2015, NEW ENGL J MED, V372, P1791, DOI 10.1056/NEJMoa1500857eng
hcfmusp.relation.referenceCadroy Y, 2000, CIRCULATION, V101, P2823, DOI 10.1161/01.CIR.101.24.2823eng
hcfmusp.relation.referenceCannon CP, 2017, NEW ENGL J MED, V377, P1513, DOI 10.1056/NEJMoa1708454eng
hcfmusp.relation.referenceCao D, 2021, EUR HEART J, V42, P339, DOI 10.1093/eurheartj/ehaa824eng
hcfmusp.relation.referenceCapodanno D, 2022, NAT REV CARDIOL, V19, P117, DOI 10.1038/s41569-021-00598-1eng
hcfmusp.relation.referenceCapodanno D, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.019432eng
hcfmusp.relation.referenceCapodanno D, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.017212eng
hcfmusp.relation.referenceCapodanno D, 2019, J AM COLL CARDIOL, V74, P83, DOI 10.1016/j.jacc.2019.05.016eng
hcfmusp.relation.referenceCapodanno D, 2018, J AM COLL CARDIOL, V72, P2915, DOI 10.1016/j.jacc.2018.09.057eng
hcfmusp.relation.referenceCapodanno D, 2018, NAT REV CARDIOL, V15, P480, DOI 10.1038/s41569-018-0049-1eng
hcfmusp.relation.referenceChiarito M, 2022, JACC-CARDIOVASC INTE, V15, P282, DOI 10.1016/j.jcin.2021.11.005eng
hcfmusp.relation.referenceChiarito M, 2020, LANCET, V395, P1487, DOI 10.1016/S0140-6736(20)30315-9eng
hcfmusp.relation.referenceChichareon P, 2020, JACC-CARDIOVASC INTE, V13, P634, DOI 10.1016/j.jcin.2019.12.018eng
hcfmusp.relation.referenceCho JY, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.120.019630eng
hcfmusp.relation.referenceCollins R, 2009, LANCET, V373, P1849, DOI 10.1016/S0140-6736(09)60503-1eng
hcfmusp.relation.referenceDangas G, 2022, EUROINTERVENTION, V17, P1330, DOI 10.4244/EIJ-D-21-00721eng
hcfmusp.relation.referenceDangas G, 2020, J AM COLL CARDIOL, V75, P2414, DOI 10.1016/j.jacc.2020.03.011eng
hcfmusp.relation.referenceDehghani P, 2022, EUR HEART J-CARD PHA, V8, P707, DOI 10.1093/ehjcvp/pvac016eng
hcfmusp.relation.referenceDewilde WJM, 2013, LANCET, V381, P1107, DOI 10.1016/S0140-6736(12)62177-1eng
hcfmusp.relation.referenceEikelboom JW, 2017, NEW ENGL J MED, V377, P1319, DOI 10.1056/NEJMoa1709118eng
hcfmusp.relation.referenceEscaned J, 2021, EUR HEART J, V42, P4624, DOI 10.1093/eurheartj/ehab702eng
hcfmusp.relation.referenceFranchi F, 2019, JACC-BASIC TRANSL SC, V4, P763, DOI 10.1016/j.jacbts.2019.07.011eng
hcfmusp.relation.referenceFranzone A, 2020, EUROINTERVENTION, V16, P627, DOI 10.4244/EIJ-D-20-00145eng
hcfmusp.relation.referenceFranzone A, 2019, J AM COLL CARDIOL, V74, P2223, DOI 10.1016/j.jacc.2019.08.1038eng
hcfmusp.relation.referenceGao C, 2020, CARDIOVASC DIABETOL, V19, DOI 10.1186/s12933-020-01153-xeng
hcfmusp.relation.referenceGargiulo G, 2019, EUR HEART J, V40, P3757, DOI 10.1093/eurheartj/ehz732eng
hcfmusp.relation.referenceGent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3eng
hcfmusp.relation.referenceGiacoppo D, 2021, EUR HEART J, V42, P308, DOI 10.1093/eurheartj/ehaa739eng
hcfmusp.relation.referenceGibson CM, 2016, NEW ENGL J MED, V375, P2423, DOI 10.1056/NEJMoa1611594eng
hcfmusp.relation.referenceGragnano F, 2022, J AM HEART ASSOC, V11, DOI 10.1161/JAHA.121.024291eng
hcfmusp.relation.referenceHahn JY, 2019, JAMA-J AM MED ASSOC, V321, P2428, DOI 10.1001/jama.2019.8146eng
hcfmusp.relation.referenceHan YL, 2022, CIRC-CARDIOVASC INTE, V15, DOI 10.1161/CIRCINTERVENTIONS.120.009495eng
hcfmusp.relation.referenceHan YL, 2022, J AM COLL CARDIOL, V79, P116, DOI 10.1016/j.jacc.2021.10.028eng
hcfmusp.relation.referenceHennigan BW, 2022, PLATELETS, V33, P141, DOI 10.1080/09537104.2020.1863937eng
hcfmusp.relation.referenceHINDRICKS G, 2020, EUR HEART J, DOI [10.1093/eurheartj/ehaa612, DOI 10.1093/EURHEARTJ/EHAA612]eng
hcfmusp.relation.referenceHirsh J, 2004, ARCH INTERN MED, V164, P2106, DOI 10.1001/archinte.164.19.2106eng
hcfmusp.relation.referenceIbanez B, 2018, KARDIOL POL, V76, P229, DOI 10.5603/KP.2018.0041eng
hcfmusp.relation.referenceJanuary CT, 2019, J AM COLL CARDIOL, V74, P104, DOI 10.1016/j.jacc.2019.01.011eng
hcfmusp.relation.referenceJohnson TW, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016495eng
hcfmusp.relation.referenceKanenawa K, 2021, CIRC-CARDIOVASC INTE, V14, DOI 10.1161/CIRCINTERVENTIONS.120.010007eng
hcfmusp.relation.referenceKim BK, 2020, JAMA-J AM MED ASSOC, V323, P2407, DOI 10.1001/jama.2020.7580eng
hcfmusp.relation.referenceKim BG, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.121.022700eng
hcfmusp.relation.referenceKim HK, 2021, THROMB HAEMOSTASIS, V121, P422, DOI 10.1055/s-0040-1718729eng
hcfmusp.relation.referenceKirchhof P, 2016, EUROPACE, V18, DOI [10.1093/europace/euw295, 10.1016/j.rec.2016.11.033, 10.5603/KP.2016.0172]eng
hcfmusp.relation.referenceKnuuti J, 2020, EUR HEART J, V41, P407, DOI 10.1093/eurheartj/ehz425eng
hcfmusp.relation.referenceKogame N, 2020, JACC-CARDIOVASC INTE, V13, P2251, DOI 10.1016/j.jcin.2020.06.023eng
hcfmusp.relation.referenceKogame N, 2019, EUROINTERVENTION, V15, pE547, DOI 10.4244/EIJ-D-19-00131eng
hcfmusp.relation.referenceKoo BK, 2021, LANCET, V397, P2487, DOI 10.1016/S0140-6736(21)01063-1eng
hcfmusp.relation.referenceLawton JS, 2022, CIRCULATION, V145, pE18, DOI 10.1161/CIR.0000000000001038eng
hcfmusp.relation.referenceLee SH, 2021, EUROINTERVENTION, V17, pE888, DOI 10.4244/EIJ-D-21-00223eng
hcfmusp.relation.referenceLee SJ, 2021, JACC-CARDIOVASC INTE, V14, P431, DOI 10.1016/j.jcin.2020.11.036eng
hcfmusp.relation.referenceLevine GN, 2016, J AM COLL CARDIOL, V68, P1082, DOI 10.1016/j.jacc.2016.03.513eng
hcfmusp.relation.referenceLopes RD, 2019, JAMA CARDIOL, V4, P747, DOI 10.1001/jamacardio.2019.1880eng
hcfmusp.relation.referenceLopes RD, 2019, NEW ENGL J MED, V380, P1509, DOI 10.1056/NEJMoa1817083eng
hcfmusp.relation.referenceMehran R, 2019, NEW ENGL J MED, V381, P2032, DOI 10.1056/NEJMoa1908419eng
hcfmusp.relation.referenceMoon JY, 2018, PROG CARDIOVASC DIS, V60, P478, DOI 10.1016/j.pcad.2017.12.004eng
hcfmusp.relation.referenceNeumann F-J., 2019, HEART J, V40, P165, DOI 10.1093/EURHEARTJ/EHY394eng
hcfmusp.relation.referenceO'Donoghue ML, 2020, CIRCULATION, V142, P538, DOI 10.1161/CIRCULATIONAHA.120.046251eng
hcfmusp.relation.referenceOno M, 2022, EUROINTERVENTION, V18, pE377, DOI 10.4244/EIJ-D-21-00870eng
hcfmusp.relation.referenceOno M, 2022, EUR HEART J-CARD PHA, V8, P39, DOI 10.1093/ehjcvp/pvaa110eng
hcfmusp.relation.referencePalmerini T, 2013, J AM COLL CARDIOL, V62, P1915, DOI 10.1016/j.jacc.2013.08.725eng
hcfmusp.relation.referenceRingleb PA, 2004, STROKE, V35, P528, DOI 10.1161/01.STR.0000110221.54366.49eng
hcfmusp.relation.referenceRoffi M, 2016, EUR HEART J, V37, P267, DOI 10.1093/eurheartj/ehv320eng
hcfmusp.relation.referenceRoh JW, 2021, CARDIOL J, V28, P855, DOI 10.5603/CJ.a2021.0101eng
hcfmusp.relation.referenceSerruys PW, 2019, EUR HEART J, V40, P2595, DOI 10.1093/eurheartj/ehz453eng
hcfmusp.relation.referenceSetih AG, 2021, EUR HEART J, V42, P2998eng
hcfmusp.relation.referenceSibbing D, 2019, JACC-CARDIOVASC INTE, V12, P1521, DOI 10.1016/j.jcin.2019.03.034eng
hcfmusp.relation.referenceStefanini GG, 2021, EUR HEART J, V42, P4683, DOI 10.1093/eurheartj/ehab533eng
hcfmusp.relation.referenceSteg PG, 2019, NEW ENGL J MED, V381, P1309, DOI 10.1056/NEJMoa1908077eng
hcfmusp.relation.referenceStone GW, 2013, LANCET, V382, P614, DOI 10.1016/S0140-6736(13)61170-8eng
hcfmusp.relation.referenceStone GW, 2011, NEW ENGL J MED, V364, P226, DOI 10.1056/NEJMoa1002358eng
hcfmusp.relation.referenceStorey RF, 2000, BRIT J HAEMATOL, V110, P925, DOI 10.1046/j.1365-2141.2000.02208.xeng
hcfmusp.relation.referenceTakahashi K, 2020, EUROINTERVENTION, V16, P634, DOI 10.4244/EIJ-D-19-00498eng
hcfmusp.relation.referenceTakahashi K, 2020, INT J CARDIOL, V320, P27, DOI 10.1016/j.ijcard.2020.07.042eng
hcfmusp.relation.referenceTakahashi K, 2019, J AM COLL CARDIOL, V74, P2015, DOI 10.1016/j.jacc.2019.08.997eng
hcfmusp.relation.referenceTomaniak M, 2020, EUROINTERVENTION, V15, P1125, DOI 10.4244/EIJY19M10_01eng
hcfmusp.relation.referenceTomaniak M, 2019, JAMA CARDIOL, V4, P1092, DOI 10.1001/jamacardio.2019.3355eng
hcfmusp.relation.referenceUS National Library of Medicine, USeng
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublicatione5f6197a-e11d-4b47-af40-0542e85351f2
relation.isAuthorOfPublication.latestForDiscoverye5f6197a-e11d-4b47-af40-0542e85351f2
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_CAPODANNO_P2Y12_inhibitor_monotherapy_in_patients_undergoing_percutaneous_coronary_2022.PDF
Tamanho:
2.33 MB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/11
Artigos e Materiais de Revistas Científicas - ODS/03